Comparison

Pathoconnect Phlebo vs SwiftDraws App

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

Pathoconnect Phlebo

Features
Read full description

The app is for phlebotomist to automate the specimen sample collection process. Phlebotomist can see the assigned order to them with patient's information as well as the sample to be collected. Further, phlebotomist can enter order related information and mark the order as completed.

About

SwiftDraws App

Features
Read full description

SwiftDraws: Mobile Order Tracking & Phlebotomy Management SwiftDraws is an all-in-one solution designed for laboratories, mobile phlebotomists, and home-draw teams. Built for speed, compliance, and visibility, SwiftDraws enables real-time mobile order tracking, streamlined specimen collection, and efficient team coordination in the field. Whether you’re managing home draws, clinic pickups, or lab dispatches—SwiftDraws keeps everything in sync. Key Features - Live Order Tracking Track phlebotomy orders on the go with real-time updates, GPS-enabled routing, and role-based access. - Smart Collection Workflows Capture notes, upload documents and signatures, and mark orders complete with automated timestamping. - Team Assignments & Scheduling Assign orders to phlebotomists, view availability, and coordinate routes based on ZIP code or territory coverage. - Label Printing & Document Uploads Print barcoded labels directly from the app and securely upload insurance cards, licenses, or requisition forms. - HIPAA-Ready & Role-Based Access Built with compliance in mind—only see what you’re authorized to, whether you're an Admin, Phlebotomist, or Lab Manager. - Dashboards & Reporting Monitor daily operations, track productivity, and export order data with flexible reporting tools. Perfect For: Mobile Phlebotomy Companies Clinical & Reference Labs Home Health Providers Diagnostic Centers Logistics Teams Supporting Lab Orders SwiftDraws turns phlebotomy logistics into a streamlined, mobile-first experience—saving time, reducing errors, and improving patient care.

Screenshots

Pathoconnect Phlebo4 screens
SwiftDraws App4 screens

Verdict

The call

The clearest difference is update cadence: Pathoconnect Phlebo at weekly against SwiftDraws App's every 4 months. Pathoconnect Phlebo also leads on iOS requirement (15.1 vs 17.0). On price, ads, in-app purchases and device support there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

UpkeepUpdate frequency

Pathoconnect Phlebo ships an update weekly, SwiftDraws App every 4 months. The most recent releases landed on October 20, 2026 and October 7, 2026 respectively.

Scorecard2 real differences · 4 level
Pathoconnect Phlebo versus SwiftDraws App: the parameters behind the verdict, then further details
ParameterPathoconnect PhleboSwiftDraws App
PriceFreeFree
Update frequencyWeekly — betterEvery 4 months
AdsNoNo
In-app purchasesNoNo
DevicesiPhone, iPodiPhone, iPad
Requires iOS15.1 — better17.0
Further details — not scored
Size32 MB23 MB
Age rating4+4+
DeveloperObservance SolutionsKamran Alison

In-app purchases

None

Pathoconnect Phlebo

No in-app purchases

None

SwiftDraws App

No in-app purchases

Questions

Is Pathoconnect Phlebo free?
Pathoconnect Phlebo is free to download, with no in-app purchases.
Is SwiftDraws App free?
SwiftDraws App is free to download, with no in-app purchases.
Do Pathoconnect Phlebo or SwiftDraws App have ads?
Neither Pathoconnect Phlebo nor SwiftDraws App shows ads.
Which is updated more often, Pathoconnect Phlebo or SwiftDraws App?
Pathoconnect Phlebo ships an update weekly, and SwiftDraws App every 4 months. Most recently, Pathoconnect Phlebo was updated on October 20, 2026 and SwiftDraws App on October 7, 2026.

Other comparisons